Search

Your search keyword '"Nielsen, Ulrik"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Nielsen, Ulrik" Remove constraint Author: "Nielsen, Ulrik" Database MEDLINE Remove constraint Database: MEDLINE
44 results on '"Nielsen, Ulrik"'

Search Results

1. Recurrent Laryngeal Papillomatosis in Denmark from 1994 to 2021: A Nationwide Register Study.

2. Identification and high-throughput genotyping of single nucleotide polymorphism markers in a non-model conifer (Abies nordmanniana (Steven) Spach).

3. Estimating waves via measured ship responses.

4. Accumulated effects of factors determining plant development from somatic embryos of Abies nordmanniana and Abies bornmuelleriana .

5. Weighted single-step genomic best linear unbiased prediction integrating variants selected from sequencing data by association and bioinformatics analyses.

6. Improvement of genomic prediction by integrating additional single nucleotide polymorphisms selected from imputed whole genome sequencing data.

7. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.

8. Bioreactor-based advances in plant tissue and cell culture: challenges and prospects.

9. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

10. Association analysis for young stock survival index with imputed whole-genome sequence variants in Nordic Holstein cattle.

11. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).

12. A 0.5-Mbp deletion on bovine chromosome 23 is a strong candidate for stillbirth in Nordic Red cattle.

13. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.

14. Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).

15. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.

16. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.

17. Across-country test-day model evaluations for Holstein, Nordic Red Cattle, and Jersey.

18. Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.

19. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.

20. Insulin-like growth factor promotes cardiac lineage induction in vitro by selective expansion of early mesoderm.

21. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.

22. A 660-Kb deletion with antagonistic effects on fertility and milk production segregates at high frequency in Nordic Red cattle: additional evidence for the common occurrence of balancing selection in livestock.

23. Novel harmful recessive haplotypes identified for fertility traits in Nordic Holstein cattle.

24. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.

25. Rapid optimization and prototyping for therapeutic antibody-like molecules.

26. Comparison on genomic predictions using three GBLUP methods and two single-step blending methods in the Nordic Holstein population.

27. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.

28. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

29. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

30. Building and characterizing antibody-targeted lipidic nanotherapeutics.

31. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.

32. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.

33. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

34. Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data.

35. A novel assay for monitoring internalization of nanocarrier coupled antibodies.

36. Systems biology and combination therapy in the quest for clinical efficacy.

37. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

38. The response of human epithelial cells to TNF involves an inducible autocrine cascade.

39. A data-driven computational model of the ErbB receptor signaling network.

40. Using computational modeling to drive the development of targeted therapeutics.

41. Multiplexed sandwich assays in microarray format.

42. Profiling receptor tyrosine kinase activation by using Ab microarrays.

43. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.

44. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Catalog

Books, media, physical & digital resources